Cencora (COR)

• Market cap: $47.1B
• 1 day: -1.30%
• 5 days: -3.52%
• 1 month: 3.05%
• 3 months: 1.51%
• 6 months: 8.31%
• Year to date: 15.20%
• 1 year: 24.33%
• 5 years: 34.29%
• 10 years: 169.90%
• Sector: Healthcare
• Industry: Drugs, Proprietaries & Druggists Sundries

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

106% more call options, than puts

Call options by funds: $1.69B | Put options by funds: $819M

19% more repeat investments, than reductions

Existing positions increased: 446 | Existing positions reduced: 376

0% more funds holding

Funds holding: 1,115 [Q2] → 1,115 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 125 | Existing positions closed: 125

5% less capital invested

Capital invested by funds: $45.2B [Q2] → $43B (-$2.19B) [Q3]

3.55% less ownership

Funds ownership: 100.58% [Q2] → 97.04% (-3.55%) [Q3]

22% less funds holding in top 10

Funds holding in top 10: 18 [Q2] → 14 (-4) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $245 2% upside
• Avg. target: $277 15% upside
• High target: $292 22% upside

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

Baird David Rodgers 69% 1-year accuracy 9 / 13 met price target	22% upside $292	Outperform Maintained	7 Nov 2024
UBS Kevin Caliendo 81% 1-year accuracy 13 / 16 met price target	19% upside $285	Buy Maintained	7 Nov 2024
Barclays Stephanie Davis 59% 1-year accuracy 10 / 17 met price target	21% upside $290	Overweight Maintained	7 Nov 2024
Evercore ISI Group John Belton 100% 1-year accuracy 3 / 3 met price target	19% upside $285	Outperform Maintained	7 Nov 2024
Evercore ISI Group John Belton 100% 1-year accuracy 3 / 3 met price target	4% upside $250	Outperform Maintained	8 Oct 2024